Skip to main content
. Author manuscript; available in PMC: 2022 May 13.
Published in final edited form as: Curr Hypertens Rep. 2021 May 13;23(5):29. doi: 10.1007/s11906-021-01147-4

Figure 1.

Figure 1.

Comparison between Physiological Effects of OCP use (blue/on left) and HDP/Preeclampsia (red/on right). *

*Contains studies done in both humans and animal models

AT1AA= angiotensin II type-1 receptor autoantibodies, VEGF= vascular endothelial growth factor, sFlt-1= soluble fms-like tyrosine kinase-1.